-$0.05 EPS Expected for Oxford Immunotec Global PLC (NASDAQ:OXFD) This Quarter

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post earnings per share of ($0.05) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Oxford Immunotec Global’s earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.09). Oxford Immunotec Global reported earnings per share of ($0.25) during the same quarter last year, which would indicate a positive year over year growth rate of 80%. The company is expected to announce its next earnings report before the market opens on Tuesday, August 6th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full-year earnings of ($0.24) per share for the current financial year, with EPS estimates ranging from ($0.27) to ($0.19). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.20) to ($0.13). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.14. The company had revenue of $14.79 million during the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company’s quarterly revenue was up 26.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.40) EPS.

Several analysts have recently commented on OXFD shares. ValuEngine downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, July 23rd. BidaskClub raised shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Saturday. TheStreet downgraded shares of Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research report on Monday, July 15th. Finally, Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC lifted its holdings in shares of Oxford Immunotec Global by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock worth $247,000 after purchasing an additional 5,120 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Oxford Immunotec Global in the 1st quarter worth $1,185,000. Millennium Management LLC lifted its holdings in shares of Oxford Immunotec Global by 117.2% in the 4th quarter. Millennium Management LLC now owns 117,914 shares of the company’s stock worth $1,507,000 after purchasing an additional 63,617 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Oxford Immunotec Global by 0.7% in the 4th quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock worth $3,715,000 after purchasing an additional 2,113 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Oxford Immunotec Global by 15.9% in the 4th quarter. Geode Capital Management LLC now owns 101,930 shares of the company’s stock worth $1,302,000 after purchasing an additional 13,974 shares in the last quarter. Institutional investors own 91.19% of the company’s stock.

Shares of OXFD stock traded up $0.17 during trading hours on Friday, hitting $13.21. 149,349 shares of the company were exchanged, compared to its average volume of 185,511. The stock has a market capitalization of $343.44 million, a price-to-earnings ratio of 25.90 and a beta of 0.33. Oxford Immunotec Global has a fifty-two week low of $11.88 and a fifty-two week high of $19.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60. The company’s 50 day simple moving average is $13.49.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Further Reading: Why do analysts give a neutral rating?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.